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Abstract
Background: Development of T-cells based-Interferon gamma (IFNc) assays has offered new possibilities for the diagnosis
of latent tuberculosis infection (LTBI) and active disease in adults. Few studies have been performed in children, none in
France. With reference to the published data on childhood TB epidemiology in the Paris and Ile de France Region, we
considered it important to evaluate the performance of IGRA (QuantiFERON TB Gold In TubeH, QF-TB-IT) in the diagnosis and
the follow-up through treatment of LTBI and active TB in a cohort of French children.
Methodology/Principal Findings: 131 children were recruited during a prospective and multicentre study (October 2005
and May 2007; Ethical Committee St Louis Hospital, Paris, study number 2005/32). Children were sampled at day 0, 10, 30, 60
(except Healthy Contacts, HC) and 90 for LTBI and HC, and a further day 120, and day 180 for active TB children. Median age
was 7.4 years, with 91% of the children BCG vaccinated. LTBI and active TB children undergoing therapy produced
significant higher IFNc values after 10 days of treatment (p=0.035). In addition, IFNc values were significantly lower at the
end of treatment compared to IFNc values at day 0, although the number of positive patients was not significantly different
between day 0 and end of treatment.
Conclusions/ Significance: By following quantitative IFNc values in each enrolled child with LTBI or active TB and receiving
treatment, we were able to detect an increase in the IFNc response at day 10 of treatment which might allow the
confirmation of a diagnosis. In addition, a decline in IFNc values during treatment makes it possible for clinicians to monitor
the effect of preventive or curative therapy.
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Introduction
Mycobacterium tuberculosis (MTB) still represents one of the most
important killers among infectious pathogens. 9.2 million new
tuberculosis (TB) cases in the world were reported in 2006 giving a
total prevalence of 14.2 million of cases when previously diagnosed
and cases undergoing treatment are included [1]. Many
developing countries still notify the bulk of TB cases, which
confer a major risk for susceptible individuals to become infected
by tubercle bacilli. Children belong to this category of susceptible
individuals. Younger children are the most likely to develop active
TB after contact with an active TB case, and by so doing are
considered key indicators of MTB transmission in the community
[2,3]. The risk of developing active TB following acute infection is
high (20–40%) in children aged between 0 and 5 years, compared
to adults. The risk then decreases as age increases [2,3].
However, childhood TB remains a neglected aspect of the TB
epidemic because it is usually a paucibacillary acid fast smear
negative disease, and is thus considered to make a relatively minor
contribution to the spread of TB [4–6]. Childhood TB presents
with a diversity of manifestations, both pulmonary and extrapul-
monary. In addition, there is little prospect of achieving a widely
available gold standard diagnosis for TB in children, either by
means of microscopy, culture, PCR or serology [2,7,8]. Less than
one half of active TB in children is culture proven, and PCR,
despite its rapidity, is unable to improve on this [2]. At present,
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4130clinicians must rely on clinical criteria, the patient history, chest
radiography and tuberculin skin testing (TST). None of these
approaches is totally accurate, often leading to over diagnosis
of TB in children who might then be unnecessarily treated for
TB.
France belongs to the WHO Group 3 with an incidence rate
8.5/100,000 in 2006 [9]. However, this overall incidence rate may
not be truly representative. Young adults and children less than 20
years old represent 10% of the TB case-load [9]. Paris and Ile de
France Region, where our study was conducted possess an
incidence rate nearly 3 times higher than our national incidence
rate [9], and in several areas, close to incidence rate observed in
some high burden countries described above. Without the
assurance of an accurate diagnosis, the precise burden of
childhood TB and its importance will remain uncertain and
controversial.
The recent description and availability of Interferon-gamma
release assays (IGRA); the QuantiFERONH-TB Gold In-Tube
(QF-TB-IT, Cellestis, Australia) and the T-SPOT TB (T-SPOTH,
Oxford Immunotec Ltd. UK); offers new possibilities for the
diagnosis of latent TB infection (LTBI) and active TB in adults
[10]. IGRA allow detection of circulating TB specific T-cells in
vitro using either an ‘‘In Tube’’ whole blood or ELISPOT
approach [10 and references therein]. By comparison, few studies
have been performed in children [11–24]. In France only one
adult study has been published so far [25] and none on childhood
TB. Taking advantage of the ease of use with QF-TB-IT usage,
and with reference to the published data on childhood TB
epidemiology in the Paris and Ile de France Region, we considered
it important to evaluate the performance of IGRA in the diagnosis
of LTBI and active TB in a French children cohort in one of the
highest TB incidence area in France. In addition, we evaluate
IGRA by measuring the IFNc response at day 10, 30, 60, 90 in
treated LTBI children and an additional day 120 and 180 in
treated active TB children. Results presented in this study allowed
us to provide a comprehensive follow-up data on IFNc response
during treatment for latent TB infection and active TB disease in
children.
Methods
Objectives
We conducted a prospective and multicentre study between
October 2005 and May 2007, involving 5 hospitals located in Paris
and North of Ile de France Region to evaluate the intrinsic
performance of IGRA in a French children cohort with latent TB
infection or active TB disease, and to monitor the IFNc responses
in these children, receiving antituberculous prophylaxis or
therapy.
Participants
Enrolled children were investigated according to the national
guidelines published by La Socie ´te ´ de Pneumologie de Langue
Franc ¸aise [26] and Le Conseil Supe ´rieur d’Hygie `ne Publique de
France [27]. The study was performed blind as clinicians
responsible were not provided the QF-TB-IT results throughout
the study. The distribution of the children in the different groups,
as described below, was performed by clinicians mainly based on
patient history, clinical data, chest radiography, microbiological
results and TST.
Healthy contacts were defined by clinicians as asymptomatic
children with a suspicion of TB contact but with a negative TST
or without a TST conversion, and normal chest radiography.
LTBI children were defined as any children for whom contact
with an adult with TB is suspected, in addition to the different
inclusion criteria described above and a positive TST (see below)
Active TB children were defined as any children with the above
criteria and who had clinical signs and/or compatible chest
radiographic abnormalities, and who responded to specific
treatment for TB.
Exclusion criteria were active TB diagnosed and treated in the
two years preceding the study, contact with a known TB adult case
already treated for 3 months, recent travel in a highly endemic
country, immunosuppression (HIV, transplant, treatment…) or
any immune deficiency suspected or diagnosed and involving the
humoral and cellular immunity, and finally absence of consent.
Control children were included based on strict inclusion criteria:
children hospitalized for any disease other than tuberculosis,
absence of known contact with an adult TB case, and signed
consent by both parents and children. TST was not performed on
control children (Ethical Committee recommendations), and only
previous TST values (when known by the parents) were recorded.
Control children were matched with age with latently infected or
active TB children.
Children diagnosed with LTBI received chemoprophylaxis for a
period of 3 months (Isoniazid+Rifampicin) and were followed up
at day 0 (day of inclusion), 10, 30, 60 and 90 (end of treatment).
Any child diagnosed with active TB was hospitalized and received
chemotherapy (Isoniazid+Rifampicin+Pyrazinamide+/2Etham-
butol) for the first two months and dual therapy (Isoniazid+Ri-
fampicin) for the following four months. Children with active TB
were followed up at day 0 (day of inclusion), 10, 30, 60, 90, 120,
180 (end of treatment). Finally, children considered as healthy
contacts without LTBI were also followed up as for children with
LTBI (except day 60) as nearly all received chemoprophylaxis
(83%).
Description of Procedures undertaken
The TST was performed by experienced nurses or paediatri-
cians in antiTB centres called ‘‘Centre de Lutte Antituberculeuse’’
or in a medical ward organised in schools, or social centres,
according to standard national guidelines using intradermal
injection of 5 U of PPD (Tubertest H Aventis Pasteur MSD,
Lyon, France). The transverse induration was read at 72 h. TST
was considered positive when: (i) a TST induration diameter
$10 mm if non BCG vaccinated or BCG vaccinated but with a
known close TB contact case; (ii) a TST induration greater than
15 mm if BCG vaccinated with unknown TB contact case; (iii) and
TST conversion defined as an increase of TST induration
diameter $10 mm when compared to a previous TST induration
diameter measured before (mainly after BCG vaccination, when
children entered nursery or are sent to school) [27]. Children
suspected of being a TB contact with or without a positive TST, or
who had clinical signs were then referred to the Pediatric hospital
or a hospital with paediatric ward present in the same area or
suburb, where clinicians participating in the study attended. TST
was never done again at the hospital when the induration diameter
was recently known.
The QF-TB-IT was sampled at day of inclusion (day 0) for all
children. QF-TB-IT was then sampled by nurses or paediatricians
during the normal follow-up and outpatient visit for the HC, LTBI
(day 10, 30, 60 (except HC) and 90) and an additional day 120 and
180 for active TB children.
The supplier’s recommendations were strictly followed. A
positive test result was defined as .0.35 IU/ml. The QFT-TB-
IT ELISA does not accurately determine IFN-c concentrations
greater than 10 IU/mL. Thus, to enable estimation of IFN-c
Childhood TB-IFNc Assays
PLoS ONE | www.plosone.org 2 January 2009 | Volume 4 | Issue 1 | e4130concentrations in plasma samples with values above 10 IU/ml,
these samples were diluted 1/2 and 1/10 in the ELISA buffer
reagent and retested in the ELISA. Concentrations were then
calculated from the OD of the diluted plasma sample which fell
within the dynamic range of the ELISA.
All children except controls, 2 HC, 17 LTBI and one active TB
children had pulmonary (sputum, gastric aspirate, bronchoalveolar
lavage…) and/or extra-pulmonary specimens when appropriate
sent to the respective mycobacteriology laboratory.
Ethics
The study was approved by the Saint Louis Hospital Ethical
Committee (CCPPRB St Louis Hospital, Paris, study number
2005/32). Parents and children signed informed consent when
accepting an invitation to participate in the study.
Statistical analysis
Patient characteristics were reported as counts (percent) or
median (range). Distributions of QF-TB-IT for all groups were
represented using box and whiskers plots. As the distribution of
QF-TB-IT was skewed, data were displayed on a log scale, and
null values were arbitrarily set at 0.01 (below the smallest observed
non-null value). QF-TB-IT positivity was defined as values equal
or superior to 0.35 (which correspond to 20.46 on the log scale).
These distributions were compared using Kruskal-Wallis tests and,
in case of a significant difference, post-hoc two by two group
comparisons were performed using Wilcoxon rank sum tests and
Hochberg’s method to correct p-values for multiple testing.
Similar analyses were conducted after adjustment for age, using
analysis of covariance of log-transformed data. The properties of
QF-TB-IT as a diagnostic marker of TB infection were assessed
using the area under the receiver operating characteristics–ROC–
curve (AUC), and estimates of sensitivity and specificity when data
were dichotomized at the usual positivity threshold. For these
analyses, TB infection was defined as children with LTBI and TB
contact or active TB. The non TB infection group was defined as
healthy contacts or children with LTBI and no TB contact.
Results of QF-TB-IT were compared in active TB children
according to culture, family contact and chest X-ray using the
signed Wilcoxon rank sum test, while the proportions of QF-TB-
IT and positive cultures were compared in these patients by the
Liddell’s exact test for paired data.
The association between TST induration diameter and QF-TB-
IT was assessed using Spearman rank correlation coefficient and the
agreement between both dichotomized tests by the kappa statistics.
To analyze the evolution of QF-TB-IT during treatment, values
were compared between day 0 and day 10 and, then, between day
0 and the date of the end of chemoprophylaxis, using paired
Wilcoxon tests (quantitative values). To avoid an increase of the
type I error rate, dichotomized test values were compared between
these time points using Liddell’s test only if a significant difference
was obtained on the quantitative values.
All tests were two-sided, and p-values ,0.05 were regarded as
indicating statistical significance. Analyses were carried out using
R 2.6.2 statistical software.
Results
1. Patients
A total of 131 children were included in 3 Parisian Pediatric
Hospitals and 2 hospitals with pediatric wards located in the North
suburb of Paris. The study participants lived in the catchment
areas served by the different hospitals and where the incidence of
TB is between 15 and ,100 per 100,000 inhabitants [28,29].
Two children were eventually excluded from the complete
analysis due to insufficient clinical data and follow-up leaving 129
children: 98 patients (healthy contacts, LTBI and active TB, see
below) and 31 controls (Table 1, Data S1). The median age was
7.4 years [range 2 months to 17 y]. Age distribution was not
significantly different in the four groups (p=0.073) (Table 1). Half
were male and half were females. 69% were born in France. The
vast majority of the children were BCG vaccinated (91%). 69% of
the children had a known TB contact, which was in 40% of cases a
family member (Table 1). This is in comparison with 45% of
known family members with a previous history of tuberculosis
(Table 1). One control child had a known family contact (a cousin
with a TST conversion only) but was finally categorized by the
treating clinician as a control because of a negative TST value
(0 mm), an absence of clinical symptoms and a normal chest X-
Ray. 83% of the children had TST induration measured.
However, when considering only the 98 patients for which TST
induration diameter was one of the inclusion criteria, 97% (95/98)
had a TST value, of whom 81.3% were positive (TST$10 mm)
(Data S1). In addition a known TST conversion was observed in
54% of the children (Table 1).
2. Clinical, radiological and bacteriological results
The study population was separated into 4 groups: controls (31
children), healthy contacts (HC) (12 children), LTBI (54 children)
and active TB (32 children). This classification was defined by
national guidelines and inclusion criteria described above. Chest
radiographic abnormalities were observed in 78%, 3.7% and 8.3%
of children with active TB, LTBI and HC respectively. 1 of 12 HC
(8.3%) had an abnormal chest X-ray (pneumomediastinum), and 2
out of 54 (3.7%) LTBI showed evidence of healed non tuberculous
infection. All the latently infected children, and the HC, were acid
fast smear and culture negative on all specimenstested (Table 2).By
comparison, 48% of children with active TB had culture positive
specimens for M. tuberculosis of whom 19% were acid fast bacilli
(AFB) smear positive (Table 2). All isolates were fully sensitive to all
drugs prescribed. 64% of children with active TB had pulmonary
tuberculosis, 36% had extrapulmonary tuberculosis. AFB smears
were positive in more children with pulmonary TB (32%) than in
children with extrapulmonary TB (8%). Similarly, a higher
proportion of children with pulmonary TB were culture positive
(58%) compared to extrapulmonary disease (33%). All children
with active TB were treated for a median duration timeof 6 months
(Table 2). One patient had to stop treatment after 2 months due to
acute drug related hepatitis. All of the LTBI children received
chemoprophylaxis for a median duration time of 3 months
(Table 2). 83% HC also received chemoprophylaxis for a median
duration time of 3 months (Table 2).
3. QF-TB-IT IFNc values at enrolment
In our study, TST was used to support the inclusion of children
into any of the diagnostic categories. By so, we presented data
regarding the behavior of QF-TB-IT only, for each category.
30%, 9%, 58% and 78% of controls, HC, LTB infected and active
TB children respectively were QF-TB-IT positive (Data S1). The
four groups differed significantly in QF-TB-IT IFNc values
(Table 3) (p,0.0001, Kruskal-Wallis test). Pairwise group
comparisons showed that QF-TB-IT IFNc distributions were
significantly different between all groups, except between controls
and HC, with in particular a significant difference in IFNc values
between LTBI and active TB (p=0.010, Wilcoxon rank sum test)
(figure 1). These results remained unchanged when adjusting
analyses for age using analysis of covariance on log-transformed
data.
Childhood TB-IFNc Assays
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infection, defined as LTBI children with a known family TB
contact (32 children) and active TB children (32 children) versus
healthy contacts (12 children) or children with LTBI and no TB
contact (22 children). The area under the ROC curve was 0.692
(figure 2). When using the supplier defined positivity threshold at
0.35, this resulted in a sensitivity of 69% (95%CI 56% to 80%) and
a specificity of 61% (42% to 78%).
Proportion of positive culture in active TB children was 48%
(15/31). This rate was significantly lower than the rate of positive
QF-TB-IT in these children (p=0.021, Liddell test). Finally, QF-
TB-IT values were not significantly different in active TB children
with positive and negative culture (p=0.26, figure 3A), positive
and negative chest X-ray (p=0.31, figure 3B) or presence of family
contact (p=0.18, figure 3C).
4. TST, QF-TB-IT correlation, age distribution
TST induration diameter and QFT-IT were significantly
correlated (Spearman rank correlation coefficient 0.39, p,0.0001)
(figure 4). However, when using the conventional thresholds (10 mm
and log10 (0.35) IU/ml), the tests poorly agreed (kappa statistics
0.08). TST induration was also found to be correlated with age
(Spearman rho 0.34, p=0.0003), but this was not the case for QF-
TB-IT (Spearman rho 0.04, p=0.66) (data not shown).
5. Kinetics of the IFN-c response throughout treatment
for HC, LTBI and active TB children
ThedistributionofQF-TB-ITvaluesduringfollow-up(DataS2)is
shown in figure 5 for each category. LTBI and active TB children
produced a significant variation between day 0 and day 10 of
treatment (p=0.035, paired Wilcoxon rank test). This is exemplified
Table 1. Characteristics of the enrolled children
Variable Controls Healthy contacts Latent TB Active TB Total
No. patients 31 12 54 32 129
Gender, no. (%)
F 14 (45) 6 (50) 26 (48) 17 (53) 63 (49)
M 17 (55) 6 (50) 28 (52) 15 (47) 66 (51)
Median age (range), ys 6.5 (0.3 to 15.6) 2.4 (0.2 to 16.9) 9.2 (0.5 to 17) 7.3 (0.9 to 17.1) 7.4 (0.2 to 17)
Country of birth, no. (%)
France 25 (81) 9 (75) 37 (69) 18 (56) 89 (69)
Southern Europe and Mediterranean 0 (0) 3 (25) 2 (4) 1 (3) 6 (5)
Africa 4 (13) 0 (0) 9 (17) 8 (25) 21 (16)
East Asia 0 (0) 0 (0) 3 (6) 3 (9) 6 (5)
Caribbean islands 0 (0) 0 (0) 1 (2) 1 (3) 2 (2)
Unknown 2 (6) 0 (0) 2 (4) 1 (3) 5 (4)
BCG vaccination, no. (%)
Yes 29 (94) 10 (83) 50 (93) 29 (91) 118 (91)
No 2 (6) 2 (17) 1 (2) 0 (0) 5 (4)
Unknown 0 (0) 0 (0) 3 (6) 3 (9) 6 (5)
Health coverage, no. (%) 28 (100) 11 (100) 48 (96) 25 (96) 112 (97)
Family contact, no. (%)
Yes 1 (3) 7 (58) 32 (59) 12 (38) 52 (40)
No 11 (35) 1 (8) 11 (20) 14 (44) 37 (29)
Unknown 19 (61) 4 (33) 11 (20) 6 (19) 40 (31)
TST induration diameter (mm), no. (%)
No. (%) tested 12 (39) 11 (92) 53 (98) 31 (97) 107 (83)
0–4 6 (50) 6 (55) 2 (4) 4 (13) 18 (17)
5–9 1 (8) 0 (0) 1 (2) 0 (0) 2 (2)
10–15 4 (33) 3 (27) 16 (30) 9 (29) 32 (30)
.15 1 (8) 2 (18) 34 (64) 18 (58) 55 (51)
TST conversion, no. (%)
No 22 (71) 8 (67) 9 (17) 9 (28) 48 (37)
Yes 1 (3) 4 (33) 44 (81) 21 (66) 70 (54)
Unknown 8 (26) 0 (0) 1 (2) 2 (6) 11 (9)
Previous tuberculosis
Child 0 (0) 0 (0) 1 (2) 1 (3) 2 (2)
Family 3 (10) 6 (50) 36 (67) 13 (41) 58 (45)
Unknown 6 (19) 1 (8) 5 (9) 5 (16) 17 (13)
doi:10.1371/journal.pone.0004130.t001
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seealsofigureS1).ThisvariationwassimilarforLTBIand activeTB
children (p=0.95, Wilcoxon rank-sum test).
When considering all enrolled children (except controls and
HC) who underwent QF-TB-IT testing at day 0, 10 and 30 (78 out
of 86); 29 were negative at day 0. 14 out of 29 became positive at
day 10. Five were still positive at day 30 and 9 became negative at
day 30. 15 out of 29 were negative at day 0 and day 10. Two out of
15 became positive at day 30. If we now considered all cases with
at least one positive value at day 0, day 10 or day 30, 44 LTBI
children out of 54 had at least one positive sample and 29 active
TB children out of 32 had at least one positive sample.
Thirty eight LTBI children had QF-TB-IT at day 0 and day 90.
QF-TB-IT IFNc values were significantly lower at day 90 as
compared to day 0 (p=0.042, paired Wilcoxon rank test) (figure 5),
but the numbers of patients with positive QF-TB-IT values ($0.35
IU/ml) at day 0 (25 out of 38, 66%) and at day 90 (19 out of 38,
50%) were not significantly different (p=0.21, Liddell test).
Twenty five active TB children had QF-TB-IT values at day 0
and day 180. QF-TB-IT IFNc values were significantly lower at
day 180 as compared to day 0 (p=0.041, paired Wilcoxon rank
test) (figure 5), however, as for LTBI patients, the numbers of
patients with positive QF-TB-IT values ($0.35 IU/ml) at day 0
and day 180 were not significantly different (21 out of 25 [84%]
vs18 out of 25 [72%], p=0.51, Liddell test).
Discussion
A key question regarding IGRA and one often asked by
clinicians is whether IGRA might replace the TST. Longitudinal
studies have correlated the size of induration with future risk of
active TB [30–32]. However, TST interpretation on a background
of in excess of 90% of individuals with a BCG vaccine has triggered
the need to develop a model for efficient screening to avoid an
excessive number of false-positive subjects and subsequent
overtreatment during contact tracing investigations [32–34 and
Table 2. Clinical, microbiological and treatment characteristics of the children population
Variable Healthy contacts Latent TB Active TB Total
No. patients 12 54 32 98
Chest X-ray, no. (%)
Negative 10 (83) 50 (93) 7 (22) 67 (68)
Positive 1 (8) 2 (4) 25 (78) 28 (29)
Not done or unknown 1 (8) 2 (4) 0 (0) 3 (3)
Bacteriology, no. (%)
Not done 2 (17) 17 (31) 1 (3) 20 (20)
Smear
Negative 10 (100) 37 (100) 25 (81) 72 (92)
Positive 0 (0) 0 (0) 6 (19) 6 (8)
Culture
Negative 10 (100) 36 (100) 16 (52) 62 (81)
Positive 0 (0) 0 (0) 15 (48) 15 (19)
Treatment, no. (%) 10 (83) 54 (100) 32 (100) 96 (98)
Median treatment duration (range), months 3 (1 to 3) 3 (2 to 6) 6 (2 to 12) 3 (1 to 12)
Treatment outcome, no. (%)
Cure or treatment completed 7 (70) 46 (85) 26 (81) 79 (82)
Treatment stop 0 (0) 0 (0) 1 (3) 1 (1)
Loss to follow-up 3 (30) 8 (15) 2 (6) 13 (14)
Transfer or still under treatment 0 (0) 0 (0) 3 (9) 3 (3)
doi:10.1371/journal.pone.0004130.t002
Table 3. QF-TB-IT distribution among all groups of patients.
QF-TB-IT (IU/ml)
No* patients No* missing data Median (Q1–Q3)N o ( % ) $0.35
Controls 31 1 0.02 (0–0.40) 9 (30%)
Healthy contact 12 1 0 (0–0.02) 1 (9%)
Latent TB 54 2 0.85 (0.06–3.75) 30 (58%)
Active TB 32 0 3.28 (0.51–13.97) 25 (78%)
(*): number
doi:10.1371/journal.pone.0004130.t003
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children, as they represent the most susceptible of the infected
contacts for future development of active TB. This is shown in our
prospective study where 46% of HC were TST positive as classified
by clinicians, and 83% received chemoprophylaxis. By comparison
only 9% of HC had a positive QF-TB-IT result.
Figure 1. Distribution of QF-TB-IT (in log10) for all groups of patients. QF-TB-IT values are displayed as a log scale, and null values were
arbitrarily set at 0.01 (below the smallest observed non-null value). Box and whiskers plots present the median, first and third quartile of the
distribution (box) and outer whiskers extend the whole range of data. QF-TB-IT positivity was defined as values equal or superior to log10 (0.35) which
correspond to -0.46 (grey line).
doi:10.1371/journal.pone.0004130.g001
Figure 2. ROC curve of QF-TB-IT to predict TB infection in LTBI with known family contact and active TB children.
doi:10.1371/journal.pone.0004130.g002
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background of in excess of 90% of individuals with a BCG vaccine
and at a time when IGRA were not yet licensed in France.
However, discussion and proposals were underway to move
towards a new TB control strategy with the abolition of BCG
vaccination, and it was important to evaluate the impact of IGRA
(in our study QF-TB-IT) on TB diagnosis in children. Up until this
time, studies examining IGRA in children in both high
[12,16,17,19,20,22,23] or low burden [11,14,15,18,21] regions
of tuberculosis infection have demonstrated a higher accuracy of
IGRA for TB except for the Connell et al and Nicol et al. studies
[14,23].
Significantly higher IFNc values were obtained from children
with active TB as compared to LTBI children. However, there was
an overlap in QF-TB-IT IFNc values between these categories (see
figure 1), not allowing a clear separation between both clinical
presentations. But this represents a major issue for IGRA [33,36].
In comparison, an adult pilot study using an ESAT-6 ELISPOT
approach, showed that lymph node TB and self healed culture
negative TB patients had higher frequencies of ESAT-6 specific
Figure 3. Distribution of QF-TB-IT (in log10) for culture positive and culture negative active TB children (A), for positive and
negative chest X-Ray (B) and for known TB family contact (C). Box and whiskers plots present the median, first and third quartile of the
distribution (box) and outer whiskers extend the whole range of data. QF-TB-IT values were displayed on a log scale, and null values were arbitrarily
set at 0.01 (below the smallest observed non-null value).
doi:10.1371/journal.pone.0004130.g003
Figure 4. Scatter-plot of TST induration diameter (in mm) and QF-TB-IT (in log10) in all patients. QF-TB-IT values were display on a log
scale, and null values were arbitrarily set at 0.01 (below the smallest observed non-null value). TST positivity was defined as values equal or superior
to 10 mm (grey line) QF-TB-IT positivity was defined as values equal or superior to log10 (0.35) which correspond to -0.46 (grey line).
doi:10.1371/journal.pone.0004130.g004
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PLoS ONE | www.plosone.org 7 January 2009 | Volume 4 | Issue 1 | e4130Figure 5. Distribution of QF-TB-IT (in log10) during follow-up, in Healthy Contacts (HC), Latent TB Infection (LTBI) and Active TB
Children. QF-TB-IT values are displayed on a log scale, and null values were arbitrarily set at 0.01 (below the smallest observed non-null value). QF-
TB-IT positivity was defined as values equal or superior to log10 (0.35) which correspond to 20.46 (grey line). LTBI and active TB children presented a
significant variation between day 0 and day 10 under treatment (p=0.035, paired Wilcoxon rank test). In LTBI, QF-TB-IT values were significantly lower
at day 90 as compared to day 0 (p=0.042, paired Wilcoxon rank test). In active TB, QF-TB-IT values were significantly lower at day 180 as compared to
day 0 (p=0.041, paired Wilcoxon rank test).
doi:10.1371/journal.pone.0004130.g005
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indicate that replicating M. tuberculosis and its antigen burden finely
control the level of T cell-IFN-c responses [38–40]. One might
expect a lower burden of M. tuberculosis antigens in our LTBI
children or in culture negative active TB children, and by
correlation a higher IFN-c response, as seen recently [37,41].
Despite the fact that several culture negative active TB children
had very high QF-TB-IT values (not shown), the geometric mean
was no different when we compared it to the geometric mean
calculated from culture positive active TB children IFN-c values,
although a trend was observed (see figure 3A).
Another hypothesis might be that above a certain level of
replicating mycobacteria, T-cell responses are not detectable in vitro
as T-cells might be exhausted or sequestered at the site of infection.
This argument was often used to explain the absence of a TST
response in patients with advanced tuberculosis. It represents one of
thedifficultiesencounteredbyIGRA,withnegative resultsobserved
in culture confirmed tuberculosis [10,12,13,23 and our study]. The
dynamics of the T-cell response during active or latent TB was
difficult to analyse and thereby to understand when only the TST
was available, as repeated intradermal injections of tuberculin can
caused a boosting effect [31], artificially enhancing the TST
response. By comparison, IGRA, based on a simple venous
puncture, might be repeated without interfering with the existing
in vivo T-cell activity. Setting up a prospective study to investigate
the effect of preventive and curative therapy on the IGRA response
over time has allowed us to detect an increase in the IFN-c response
as soon as 10 days after institution of therapy, whether it was for
LTBI or active TB. This is the first time to our knowledge that the
IFN-c response has been analyzed so shortly after institution of
treatment, and that such a rebound in the IFN-c response is
described in children. Thishas not been observed before in children
mainly because the delay between the first and the second
performed IGRA was too long; more than 1, 3, 6, 12 and 18
months dependingon the protocol [13,42]. However, an increase in
the PPD, but not ESAT-6 or CFP-10 ELISPOT response was
observedinchildren after1 month treatment inthestudy byNicol et
al. [13]. By comparison, Wilkinson et al. demonstrated a 1.8 fold
increased in the ESAT-6/CFP-10 ELISPOT response at 26 days in
LTBI and treated adults [43]. This was not observed in another
study but the first sampling after starting treatment was 5 weeks
[37]. This rebound is clearly significant in our study when
comparing QF-TB-IT values at day 0 and at day 10.
Although this result might be expected for active disease, it is more
surprising for LTBI. This rebound during chemoprophylaxis
observed in LTBI children might confirm the potential of the IGRA
to detect recently acquired infection and the presence of low level of
replicative bacteria. It could also demonstrate all the difficulties of
classifying children either as latently infected or as presenting with
active disease. Fourteen LTBI and active TB children with a negative
QF-TB-IT response at day 0 rapidly developed a positive response
after 10 days of preventive or curative therapy. In addition, two more
produced a positive response after one month of preventive therapy.
Strikingly, active TB children with a negative QF-TB-IT response at
day 0, but a positive a day 10, were all culture positive. For each child
showing an increase in IFNc concentration at day 10 and day 30 as
compared to day 0, the second test result was higher than 16% of the
first QF-TB-IT IFNc result, which is the threshold limit potentially
defined as true conversion [44]. As all children were enrolled and
treated similarly, it is unlikely that previous intradermal injection of
tuberculin, often performed several weeks before, would have been
responsible for this increase [45]. In fact (see below) several children
classified as LTBI or with active TB had negative IFNc values
throughout the follow-up study despite being referred because of a
TST switch or a TST induration diameter above 10 mm. Increases
in IFNcvalues due to previous intradermal injection of tuberculin are
often low [45], as compared to the increase observed in our study due
to treatment (see figure 5, active TB children).
The results we present here either satisfy the hypothesis of T-cell
sequestration or exhaustion and that killing bacteria lowers the
antigenic burden and restores active T-cells detectable in vitro,a s
seen in TB paradoxical reactions [46,47]; or indicate that killing
bacteria release cytosolic stores full of ESAT-6 and CFP-10
antigens into the macrophage resulting in a transient increase in
antigen presentation stimulating a larger T-cell response [42,48].
In addition, a significant decline in IFNc response was observed in
LTBI and active TB treated patients, when comparing quantita-
tive IFNc level measured by QF-TB-IT at day 0 and 90 or 180 for
LTBI and active TB children respectively. Similar declines were
also observed at 3 and 6 months in two other monitoring studies
[13,42], confirming the decrease of the antigenic and bacterial
load due to preventive or curative therapy.
Such an early rebound might allow confirmation of the
diagnosis, whether it is LTBI or active TB. It needs a prospective
study with a treatment decision using IGRA values obtained
between day 0 and day 30. In addition, such a decline in response
may help clinicians to monitor the effect of preventive and curative
therapy on latent or active infection [49,50].
Finally it demonstrates that the use of IGRA as a one-shot
strategy similar to the TST approach might not be the correct
strategy, as several LTBI or active TB children will be missed [23,
our study]. Similar results were recently obtained in a high
incidence area for TB [23]. T-SPOT-TB, when compared to TST
for the detection of active tuberculosis in children, demonstrated a
poorer sensitivity as compared to TST for a combined group of
culture-confirmed and clinically probable tuberculosis, indicating
that T-SPOT-TB can not be used to exclude active disease [23]. It
emphasizes the need for a follow-up strategy as shown in our
study, with an increase in QF-TB-IT sensitivity when combining
day 0, 10 and 30 results.
In conclusion, our results have shown the importance of
carefully recording the dynamics of the IFNc response in children.
We need to follow up on this study by implementing IGRA in any
children case contact study or in high risk children population. In
addition, repeating IGRA whether the first value is positive or
negative will provide reassurance to the clinician in his treatment
choice. This reinforces the hypothesis that high and/or rising
levels of IFNc in response to ESAT-6/CFP-10/Tb7.7 antigens
might serve as a prognostic marker, thus allowing the targeting of
those children in this category for treatment.
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